Literature DB >> 8557388

Influence of serum protein binding on the in vitro activity of anti-fungal agents.

M Schäfer-Korting1, H C Korting, W Rittler, W Obermüller.   

Abstract

Historically it has been assumed that the pharmacological effect is related to the free drug concentration. In exposing Candida albicans to itraconazole and ketoconazole serum concentration-time profiles, however, antifungal activity was not diminished despite intense albumin binding. The relevance of serum protein binding was further investigated, by in vitro susceptibility testing of C. albicans (40 clinical isolates) and Trichophyton rubrum (ten strains) against antifungal agents using microdilution tests allowing the determination of IC30- and MIC-values. The range of serum protein binding ranges from 11% with fluconazole to > 99% with itraconazole and terbinafine. The ratios of IC30- and MIC-values with and without serum protein (albumin, alpha- and gamma-globulin, human plasma) were related to the loss of susceptibility expected according to the free-drug hypothesis. A difference in the albumin effect with the test strains was not observed. With most antifungals including terbinafine, the activity declined as expected. IC30- and MIC-ratios for miconazole were 7 and 13 (observed) vs. 12-20 (expected), for fluconazole 1.5 and 3.5 vs. 1.1, for amphotericin B 10 vs. 11-20, for griseofulvin 3.6 vs. 4, and for terbinafine 61 vs. 100. Itraconazole activity, however, was not diminished by albumin (expected ratio 286), and ketoconazole effects decreased less than expected (ratio 5-15, expected about 100). alpha-globulin, but not gamma-globulin induced a major loss in anti-Candida activity of itraconazole and ketoconazole, which is paralleled by a decline in ketoconazole (but not itraconazole) activity due to plasma. With the other antifungals (except for ciclopiroxolamine) IC30-values for C. albicans increased, too. Due to the complete inhibition of T. rubrum growth by gamma-globulin, this species proved unsuitable for studying the gamma-globulin effects. The present study demonstrates that the effects of intense protein binding on drug activity are only partly predictable from binding studies in vitro.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8557388     DOI: 10.1007/bf01716289

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  36 in total

Review 1.  Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.

Authors:  R C Heel; R N Brogden; A Carmine; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

2.  Antimycotic susceptibility testing of dermatophytes in microcultures with a standardized fragmented mycelial inoculum.

Authors:  T C Granade; W M Artis
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

3.  Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.

Authors:  J R Perfect; D V Savani; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

4.  Inactivity of terbinafine in a rat model of pulmonary aspergillosis.

Authors:  H J Schmitt; J Andrade; F Edwards; Y Niki; E Bernard; D Armstrong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

5.  Human plasma and skin blister fluid levels of griseofulvin following a single oral dose.

Authors:  M Schäfer-Korting; H C Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Influence of protein binding on therapeutic efficacy of cefoperazone.

Authors:  L R Peterson; J A Moody; C E Fasching; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 7.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

Review 8.  Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin.

Authors:  H C Korting; M Schäfer-Korting
Journal:  Arch Dermatol       Date:  1992-02

Review 9.  Pharmacokinetic optimisation of oral antifungal therapy.

Authors:  M Schäfer-Korting
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

10.  Itraconazole in antifungal therapy.

Authors:  J D Cleary; J W Taylor; S W Chapman
Journal:  Ann Pharmacother       Date:  1992-04       Impact factor: 3.154

View more
  12 in total

Review 1.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.

Authors:  David Andes
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Antifungal activity of micafungin in serum.

Authors:  Jun Ishikawa; Tetsuo Maeda; Itaru Matsumura; Masato Yasumi; Hidetoshi Ujiie; Hiroaki Masaie; Tsuyoshi Nakazawa; Nobuo Mochizuki; Satoshi Kishino; Yuzuru Kanakura
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

3.  Effects of serum on in vitro susceptibility testing of echinocandins.

Authors:  Zekaver Odabasi; Victor Paetznick; John H Rex; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

Review 4.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

5.  Influence of human serum on antifungal pharmacodynamics with Candida albicans.

Authors:  G G Zhanel; D G Saunders; D J Hoban; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

6.  Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors.

Authors:  Quanbo Xiong; Saad A Hassan; William K Wilson; Xiang Y Han; Gregory S May; Jeffrey J Tarrand; Seiichi P T Matsuda
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 7.  Pharmacokinetics/pharmacodynamics of echinocandins.

Authors:  U Theuretzbacher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10-14       Impact factor: 3.267

8.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum.

Authors:  Antigoni Elefanti; Johan W Mouton; Katerina Krompa; Rafal Al-Saigh; Paul E Verweij; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

10.  Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi.

Authors:  Brian G Oliver; Peter M Silver; Chelsea Marie; Samantha J Hoot; Sarah E Leyde; Theodore C White
Journal:  Microbiology       Date:  2008-03       Impact factor: 2.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.